Figure 1.
Clinical characteristics of CarHLH in patients receiving CD22 CAR T cells. (A) Criteria used for identification of carHLH on this study. (B) Schematic of immune-associated toxicities of CD22 CAR T cells stratified by CRS and subsequent development of carHLH. Among 68 enrolled subjects, 8 were not infused and 1 subject (subject 20) was deemed unevaluable for CAR toxicity due to the necessity to treat with high-dose chemotherapy due to rapid leukemia progression prior to CAR T-cell expansion and thus was not included in subsequent analysis. A total of 59 subjects were evaluable for CAR toxicity evaluation. Subsequent figures all show laboratory values and clinical parameters in relationship to CRS onset, indicated by time point = 0 and stratified by carHLH (red) to no carHLH (blue). Data are restricted to only patients who had CRS. Values which were blank or otherwise uninterpretable (eg, “hemolyzed,” “lipemic”) were excluded. Dots indicate the aggregated mean for each time point, and the error bands show the estimated 68% confidence interval. Dashed line indicates the date of CRS onset. Asterisks denote P < .05 by Mann-Whitney U test. (C) C-reactive protein; statistics for each time point are found in supplemental Table 1C. (D) Ferritin; statistics for each time point are found in supplemental Table 1D. (E) Temperature; statistics for each time point are found in supplemental Table 1E. Daily max temperature (Tmax) was obtained for each patient on each day relative to CRS onset and aggregated for the figure and statistical analysis, stratified by carHLH status. (F) Total lactate dehydrogenase (LDH); statistics for each time point are found in supplemental Table 1F. (G) Alanine aminotransferase (ALT); statistics for each time point are found in supplemental Table 1G. (H) Aspartate aminotransferase (AST); statistics for each time point are found in supplemental Table 1D. (I) Bilirubin (total); statistics for each time point are found in supplemental Table 1I. (J) Triglycerides; statistics for each time point are found in supplemental Table 1J. (K) Creatinine; statistics for each time point are found in supplemental Table 1K. (L) Absolute neutrophil count; statistics for each time point are found in supplemental Table 1L. (M) Platelet count; statistics for each time point are found in supplemental Table 1M. Daily minimum platelet count was obtained for each patient on each day relative to CRS onset and aggregated for the figure and statistical analysis, stratified by carHLH status. (N) Fibrinogen; statistics for each time point are found in supplemental Table 1N.

Clinical characteristics of CarHLH in patients receiving CD22 CAR T cells. (A) Criteria used for identification of carHLH on this study. (B) Schematic of immune-associated toxicities of CD22 CAR T cells stratified by CRS and subsequent development of carHLH. Among 68 enrolled subjects, 8 were not infused and 1 subject (subject 20) was deemed unevaluable for CAR toxicity due to the necessity to treat with high-dose chemotherapy due to rapid leukemia progression prior to CAR T-cell expansion and thus was not included in subsequent analysis. A total of 59 subjects were evaluable for CAR toxicity evaluation. Subsequent figures all show laboratory values and clinical parameters in relationship to CRS onset, indicated by time point = 0 and stratified by carHLH (red) to no carHLH (blue). Data are restricted to only patients who had CRS. Values which were blank or otherwise uninterpretable (eg, “hemolyzed,” “lipemic”) were excluded. Dots indicate the aggregated mean for each time point, and the error bands show the estimated 68% confidence interval. Dashed line indicates the date of CRS onset. Asterisks denote P < .05 by Mann-Whitney U test. (C) C-reactive protein; statistics for each time point are found in supplemental Table 1C. (D) Ferritin; statistics for each time point are found in supplemental Table 1D. (E) Temperature; statistics for each time point are found in supplemental Table 1E. Daily max temperature (Tmax) was obtained for each patient on each day relative to CRS onset and aggregated for the figure and statistical analysis, stratified by carHLH status. (F) Total lactate dehydrogenase (LDH); statistics for each time point are found in supplemental Table 1F. (G) Alanine aminotransferase (ALT); statistics for each time point are found in supplemental Table 1G. (H) Aspartate aminotransferase (AST); statistics for each time point are found in supplemental Table 1D. (I) Bilirubin (total); statistics for each time point are found in supplemental Table 1I. (J) Triglycerides; statistics for each time point are found in supplemental Table 1J. (K) Creatinine; statistics for each time point are found in supplemental Table 1K. (L) Absolute neutrophil count; statistics for each time point are found in supplemental Table 1L. (M) Platelet count; statistics for each time point are found in supplemental Table 1M. Daily minimum platelet count was obtained for each patient on each day relative to CRS onset and aggregated for the figure and statistical analysis, stratified by carHLH status. (N) Fibrinogen; statistics for each time point are found in supplemental Table 1N.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal